Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2020
Proposal for new calcineurin inhibitor listings on the Pharmaceutical Schedule
11 August 2020 - As part of PHARMAC’s Annual Tender process, PHARMAC is proposing to list two new medicines on ...
Posted by Michael Wonder on 11 Aug 2020
Alkindi approved in Australia
10 August 2020 - Diurnal Group announces that Alkindi (hydrocortisone granules in capsules for opening) has been approved by the ...
Posted by Michael Wonder on 10 Aug 2020
Can multi-criteria decision analysis be implemented into real world drug decision-making processes? A Canadian provincial experience
7 August 2020 - This paper describes the implementation of multi-criteria decision analysis into a Canadian public drug reimbursement decision-making process, ...
Posted by Michael Wonder on 10 Aug 2020
SMC - August 2020 decisions
10 August 2020 - The Scottish Medicines Consortium has today published advice accepting neratinib (Nerlynx) for the treatment of breast ...
Posted by Michael Wonder on 10 Aug 2020
Coronavirus: cancer patient's urgent plea for treatment in New Zealand
10 August 2020 - A Christchurch cancer patient is missing out on potentially life-saving treatment due to rising COVID-19 cases ...
Posted by Michael Wonder on 10 Aug 2020
Gilead submits new drug application to U.S. Food and Drug Administration for Veklury (remdesivir) for the treatment of COVID-19
10 August 2020 - Veklury is currently available in the U.S. for the treatment of severe COVID-19 under an Emergency Use ...
Posted by Michael Wonder on 10 Aug 2020
Coming of age: emerging health preference research based on established scientific standards
10 August 2020 - Value in Health themed section enhances the scientific respectability and relevance of health preference research. ...
Posted by Michael Wonder on 10 Aug 2020
Return some excess drug revenues to employers, CLHIA says in submission to PMPRB
10 August 2020 - In its submission to the Patented Medicine Prices Review Board’s draft guidelines, the Canadian Life and ...
Posted by Michael Wonder on 10 Aug 2020
Aquestive Therapeutics receives FDA fast track designation for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis
10 August 2020 - Finalising preparations for pharmacokinetic clinical trials of AQST-108. ...
Posted by Michael Wonder on 10 Aug 2020
ICER to assess treatments for lupus nephritis
10 August 2020 - Report will be subject of New England CEPAC meeting in March 2021; Open Input now being accepted ...
Posted by Michael Wonder on 10 Aug 2020
Communication@EMA
10 August 2020 - The European Medicines Agency has launched its third communication perception survey. ...
Posted by Michael Wonder on 10 Aug 2020
Stephen Hahn MD, FDA chief, is caught between scientists and the President
10 August 2020 - Many medical experts - including members of his own staff - worry about whether Dr Hahn ...
Posted by Michael Wonder on 09 Aug 2020
Ensuring access to emerging COVID-19 treatments through Medicare reimbursement policy
7 August 2020 - Effective pharmaceutical treatments for coronavirus disease 2019 (COVID-19) are urgently needed, and there has been an explosion ...
Posted by Michael Wonder on 09 Aug 2020
'Tears of joy' as new drug ready for cystic fibrosis patient
8 August 2020 - A woman waiting for the approval of a delayed drug that could save her life says ...
Posted by Michael Wonder on 08 Aug 2020
U.S. Food and Drug Administration approves Lampit (nifurtimox) for the treatment of Chagas disease in children
7 August 2020 - Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 ...